Tonix Pharmaceuticals Holding CORP 8-K filings

Tonix Pharmaceuticals highlights durable pain reduction with TNX-102 SL in fibromyalgia patients at the 7th International Congress on Controversies in Fibromyalgia.

Tonix Pharmaceuticals has regained compliance with NASDAQ's minimum bid price requirement after its shares traded above $1.00 for at least 10 consecutive business days.

Tonix Pharmaceuticals reports preliminary year-end 2024 results, highlighting a strong cash position expected to fund operations into Q1 2026 and key milestones for its fibromyalgia drug candidate.

Tonix Pharmaceuticals reports positive topline results from a Phase 1 trial of TNX-1500, a next-generation anti-CD40L mAb, supporting its potential for preventing kidney transplant rejection and treating autoimmune diseases.

Tonix Pharmaceuticals promotes Siobhan Fogarty to Chief Technology Officer, effective immediately, as the company prepares for the potential launch of TNX-102 SL for fibromyalgia.

Tonix Pharmaceuticals terminated a loan agreement, released preliminary 2024 financial results, and announced a 1-for-100 reverse stock split to maintain its NASDAQ listing.

Tonix Pharmaceuticals announced the appointment of Gary Ainsworth as Vice President, Market Access and provided updates on the expected timing of topline data for two clinical programs.

The FDA has set a PDUFA goal date of August 15, 2025, for its decision on the marketing approval of Tonix Pharmaceuticals' TNX-102 SL for the treatment of fibromyalgia.

Tonix Pharmaceuticals has increased the maximum aggregate offering price of shares under its sales agreement with A.G.P./Alliance Global Partners from $150 million to $250 million.

The FDA has accepted Tonix Pharmaceuticals' New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia.

Tonix Pharmaceuticals announced leadership team expansions, updated timelines for TNX-102 SL and TNX-1500, and provided details on clinical trial results and market opportunities.

Tonix Pharmaceuticals has expanded its leadership team with two key hires and updated the timeline for its fibromyalgia drug, TNX-102 SL, including an expected FDA decision in August 2025.

Tonix Pharmaceuticals reports that its TNX-801 vaccine candidate demonstrates less virulence than older vaccines in immune-compromised mice, supporting its potential for mpox and smallpox prevention.

Tonix Pharmaceuticals announced its third quarter 2024 financial results and provided updates on its drug development pipeline, including the submission of a New Drug Application for TNX-102 SL for fibromyalgia.

Tonix Pharmaceuticals' TNX-1700, a novel fusion protein, shows significant promise in preclinical studies for treating gastric and colorectal cancers by targeting myeloid-derived suppressor cells and enhancing the effectiveness of anti-PD-1 therapies.

Tonix Pharmaceuticals has announced a research partnership with the Kenya Medical Research Institute (KEMRI) to conduct a Phase I clinical trial for its TNX-801 mpox vaccine candidate.

Tonix Pharmaceuticals announced positive preclinical data for their mpox vaccine candidate, TNX-801, demonstrating tolerability and lack of spread in immunocompromised animals.

Tonix Pharmaceuticals shareholders approved a reverse stock split proposal but rejected a proposal to increase authorized shares at a special meeting on October 30, 2024.

Tonix Pharmaceuticals disclosed preliminary Q3 2024 results showing a decrease in revenue and a need for additional funding beyond Q1 2025.

Tonix Pharmaceuticals has received its first payment from the Defense Threat Reduction Agency (DTRA) to develop broad-spectrum antiviral agents.

Tonix Pharmaceuticals has submitted a New Drug Application to the FDA for TNX-102 SL, a potential new treatment for fibromyalgia, based on positive results from two Phase 3 clinical trials.

Tonix Pharmaceuticals has partnered with X-Chem to leverage artificial intelligence and machine learning in the development of oral broad-spectrum antivirals.

Tonix Pharmaceuticals has been granted a U.S. patent for a pre-filled autoinjector delivery system for its Zembrace SymTouch migraine medication, extending market exclusivity into 2036.

Tonix Pharmaceuticals presented data on its TNX-102 SL sublingual formulation for fibromyalgia at the 11th Global Conference on Pharmaceutics and Drug Delivery Systems, highlighting its proprietary technology and pharmacokinetic properties.

Tonix Pharmaceuticals has been granted a new U.S. patent for its Tosymra intranasal migraine treatment, further solidifying its market position.

Tonix Pharmaceuticals announced that its TNX-801 mpox vaccine candidate aligns with the World Health Organization's preferred target product profile for mpox vaccines.

Tonix Pharmaceuticals has appointed Thomas Englese as Executive Vice President of Commercial Operations and announced a delay in the submission of its New Drug Application for TNX-102 SL for fibromyalgia to October 2024.

Tonix Pharmaceuticals presented data at a symposium highlighting the potential of their TNX-801 vaccine, a synthetic horsepox vaccine, for preventing mpox, showing improved tolerability and efficacy in animal models.

Tonix Pharmaceuticals has authorized a share repurchase program of up to $10 million, funded by available cash.

Tonix Pharmaceuticals has increased the maximum offering price of shares under its sales agreement with A.G.P./Alliance Global Partners from $50 million to $150 million.